Literature DB >> 9172102

Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine.

F A Wong1, S J Juzwin, S C Flor.   

Abstract

A rapid high-performance liquid chromatographic (HPLC) method for the determination of levofloxacin in human plasma and urine has been validated. A single-step liquid-liquid extraction procedure was used to isolate levofloxacin from the biological matrix prior to quantitative analysis. The compound was separated on an Inertsil C18 reversed-phase HPLC column and quantified by measuring the UV absorbance at 330 nm. The stereospecificity was achieved in the ligand-exchange mode by incorporating chiral reagents directly into the HPLC mobile phase. Ciprofloxacin was used as the internal standard. The method was linear from 0.08 to 5.18 micrograms ml-1 of levofloxacin in plasma and from 23 to 1464 micrograms ml-1 in urine. The overall utility of the method is reflected in its high sample throughput and easy adaptability to robotic automation, thus making the procedure suitable for pharmacological and pharmacokinetic studies of levofloxacin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9172102     DOI: 10.1016/s0731-7085(96)01890-0

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  20 in total

1.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Authors:  Nelson Jumbe; Arnold Louie; Robert Leary; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; Christopher Freeman; James B Kahn; Karen Bush; Michael N Dudley; Michael H Miller; George L Drusano
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

2.  Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Nelson L Jumbe; Arnold Louie; Michael H Miller; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.

Authors:  Tyree H Kiser; Dorie W Hoody; Marilee D Obritsch; Colleen O Wegzyn; Paulus C Bauling; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).

Authors:  Michelle Nelson; Mark S Lever; Rachel E Dean; Peter C Pearce; Daniel J Stevens; Andrew J H Simpson
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

6.  Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.

Authors:  L Mark Kao; Karen Bush; Roy Barnewall; James Estep; Frederic W Thalacker; Pamela H Olson; George L Drusano; Neil Minton; Shuchean Chien; Alex Hemeryck; Michael F Kelley
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

7.  Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.

Authors:  A T Chow; C Fowler; R R Williams; N Morgan; S Kaminski; J Natarajan
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

8.  Optimal sampling schedule design for populations of patients.

Authors:  Vincent H Tam; Sandra L Preston; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.

Authors:  F Scaglione; J W Mouton; R Mattina; F Fraschini
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  HPLC Method for Determination of Enantiomeric Purity of a Novel Respiratory Fluoroquinolone: WCK 1152.

Authors:  R D Yeole; S V Lawand; S B Bhavsar; P K Deshpande
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.